GNPX 8-K SEC Filing Analysis

Latest settled — T+5d

GNPX ▼ -5.34% at T+5d

NEUTRAL call ✗ call lost -5.34% · α vs SPY -4.62% · entry $0.8610 → $0.8150

Next anchor: T+20d in 2d

Currently $0.6652 · -22.74% from $0.8610 entry

Entry anchored
May 13, 03:59 PM ET
via Databento tick

T+1d

-3.60%

call -3.60% · α -2.37%

$0.8300

settled 26d ago

T+5d

-5.34%

call -5.34% · α -4.62%

$0.8150

settled 20d ago

T+20d

—

call — · α —

—

in 2d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Genprex announced positive preclinical data for its diabetes gene therapy candidate GPX-002 (Pdx1/MafA) presented at the 2026 ASGCT Annual Meeting. The study in Type 2 diabetic mouse models showed reversal of hyperglycemia, improved beta-cell function, and increased mature insulin granules at four weeks post-treatment. This is early-stage preclinical data with no human clinical trial results or financial figures disclosed.

Actionable Insight

This is early preclinical data with no human proof-of-concept — the stock may see a short-term speculative pop but lacks a catalyst for sustained re-rating. Monitor for IND filing or partnership announcements as the next meaningful milestone. Historical performance on prior GNPX reports shows poor T+20 outcomes (avg -35%), suggesting caution on chasing preclinical news.

Key Facts

Preclinical data presented May 13, 2026 at ASGCT Annual Meeting in Boston
GPX-002 (Pdx1/MafA gene therapy) reversed hyperglycemia in Type 2 diabetic mouse models
Treatment improved beta-cell function, increased mature insulin granules, and shifted beta-cells toward a more mature state
Delivery method (endoscopic retrograde cholangiopancreatography) is technically translatable to humans
No human clinical trial data, financial figures, or regulatory milestones disclosed in this filing

Financial Impact

No financial figures disclosed in the filing

Risk Factors

Preclinical results may not translate to human clinical trials
Company has going concern risk and needs additional capital (noted in forward-looking statements)
No timeline provided for clinical development of GPX-002
Micro-cap with $9M market cap — high volatility and low liquidity risk

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

86% bullish (7 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001437749-26-016883
Document: 0001437749-26-016883-index-headers.html	0001437749-26-016883
Document: 0001437749-26-016883-index.html	0001437749-26-016883
Document: 0001437749-26-016883.txt	0001437749-26-016883

5 reports for GNPX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for GNPX — sortable, filterable
	Type				Now
May 26, 2026 14d ago	8-K NEUTRAL ★ 3/10	$0.7720 $0.7350	▼ −4.79%	▼ −6.01%	$0.6652 (−13.83%)
May 14, 2026 26d ago	8-K NEUTRAL ★ 4/10	$0.8610 $0.8150	▼ −5.34%	▼ −4.62%	$0.6652 (−22.74%)
Apr 28, 2026 6w ago	8-K NEUTRAL ★ 3/10	$0.9250 $0.9390	▲ +1.51%	▼ −0.18%	$0.6652 (−28.09%)
Apr 21, 2026 7w ago	8-K BULLISH ★ 6/10	$1.09 $0.9250	▼ −15.14%	▼ −16.22%	$0.6652 (−38.97%)
Mar 18, 2026 11w ago	8-K NEUTRAL ★ 3/10	$2.01 $1.94	▼ −3.48%	▼ −2.77%	$0.6652 (−66.91%)

US Market Status

Market Closed — Opens Thu (10h 57m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access